We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Intellia Therapeutics, Inc. (NTLA - Free Report) shares rallied 7.6% in the last trading session to close at $12.6. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.1% loss over the past four weeks.
Intellia Therapeutics’ share price gain appears to reflect growing investor confidence in its regulatory progress and financial position. The FDA accepted the biologics license application for lonvoguran ziclumeran (lonvo-z), Intellia’s investigational CRISPR-based treatment for hereditary angioedema (HAE), under Priority Review, with a March 10, 2027 decision date. Moreover, the company has secured an OrbiMed debt facility of up to $400 million in September, including $75 million upfront, helping support development and potential commercialization.
This company is expected to post quarterly loss of $0.82 per share in its upcoming report, which represents a year-over-year change of +10.9%. Revenues are expected to be $10 million, down 27.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
Intellia Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Adma Biologics (ADMA - Free Report) , another stock in the same industry, closed the last trading session 1.9% higher at $10.33. ADMA has returned 7.3% in the past month.
For Adma Biologics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.19. This represents a change of +18.8% from what the company reported a year ago. Adma Biologics currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics, Inc. (NTLA - Free Report) shares rallied 7.6% in the last trading session to close at $12.6. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.1% loss over the past four weeks.
Intellia Therapeutics’ share price gain appears to reflect growing investor confidence in its regulatory progress and financial position. The FDA accepted the biologics license application for lonvoguran ziclumeran (lonvo-z), Intellia’s investigational CRISPR-based treatment for hereditary angioedema (HAE), under Priority Review, with a March 10, 2027 decision date. Moreover, the company has secured an OrbiMed debt facility of up to $400 million in September, including $75 million upfront, helping support development and potential commercialization.
This company is expected to post quarterly loss of $0.82 per share in its upcoming report, which represents a year-over-year change of +10.9%. Revenues are expected to be $10 million, down 27.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Intellia Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Adma Biologics (ADMA - Free Report) , another stock in the same industry, closed the last trading session 1.9% higher at $10.33. ADMA has returned 7.3% in the past month.
For Adma Biologics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.19. This represents a change of +18.8% from what the company reported a year ago. Adma Biologics currently has a Zacks Rank of #3 (Hold).